Skip to main content
. Author manuscript; available in PMC: 2021 Oct 13.
Published in final edited form as: Med Decis Making. 2015 Feb 10;35(3):371–387. doi: 10.1177/0272989X15570364

Table 3.

Catalog of EQ-5D Utilities by Stage and Treatment Category

Stage at Diagnosis /Treatment Category N Mean EQ-5D Utility (SD) Median EQ-5D Utility (IQR)

Stage I 750 0.81 (0.17) 0.83 (0.23)
    Surgery 449 0.82 (0.16) 0.83 (0.23)
        Lobectomy 244 0.83 (0.16) 0.83 (0.22)
        Wedge Resection 48 0.79 (0.15) 0.80 (0.15)
        Pneumonectomy 40 0.75 (0.18) 0.80 (0.25)
        Other Primary 42 0.84 (0.13) 0.82 (0.22)
    Chemotherapy 17 0.75 (0.23) 0.82 (0.28)
    Surgery w/Chemotherapy 113 0.81 (0.14) 0.82 (0.09)
        Platinum 41 0.79 (0.18) 0.82 (0.11)
        Non-Platinum* 52 0.81 (0.11) 0.82 (0.08)
    Surgery w/Chemoradiotherapy 30 0.84 (0.13) 0.83 (0.23)
        Platinum 18 0.86 (0.12) 0.84 (0.22)
    Chest Radiation 37 0.76 (0.20) 0.82 (0.17)
    Chemoradiotherapy 32 0.76 (0.23) 0.82 (0.22)
        Platinum 17 0.77 (0.26) 0.82 (0.29)
    No Treatment 37 0.81 (0.19) 0.82 (0.24)

Stage II 232 0.77 (0.17) 0.81 (0.14)
    Surgery 56 0.80 (0.15) 0.83 (0.08)
        Lobectomy 29 0.80 (0.16) 0.82 (0.06)
    Surgery w/Chemotherapy 61 0.76 (0.18) 0.81 (0.14)
        Platinum 26 0.75 (0.18) 0.81 (0.12)
        Non-Platinum 21 0.78 (0.20) 0.81 (0.09)
    Surgery w/Chemoradiotherapy 42 0.76 (0.18) 0.79 (0.15)
        Platinum* 27 0.74 (0.21) 0.80 (0.28)
        Non-Platinum* 12 0.79 (0.14) 0.81 (0.09)
    Radiotherapy 13 0.72 (0.19) 0.80 (0.25)
    Chemoradiotherapy 28 0.78 (0.18) 0.77 (0.41)
        Platinum 16 0.81 (0.16) 0.82 (0.29)
    No Treatment 15 0.73 (0.14) 0.75 (0.25)

Stage III 649 0.77 (0.18) 0.82 (0.15)
    Surgery 31 0.79 (0.17) 0.82 (0.29)
        Lobectomy 14 0.78 (0.18) 0.84 (0.18)
    Chemotherapy 93 0.78 (0.17) 0.83 (0.15)
        Platinum 29 0.78 (0.20) 0.79 (0.24)
        Non-platinum§ 23 0.82 (0.14) 0.83 (0.29)
    Surgery w/Chemotherapy 48 0.76 (0.15) 0.80 (0.12)
        Platinum 13 0.72 (0.19) 0.79 (0.14)
        Non-Platinum* 19 0.77 (0.15) 0.82 (0.14)
    Surgery w/Chemoradiotherapy 94 0.75 (0.18) 0.80 (0.14)
        Platinum 41 0.72 (0.19) 0.82 (0.15)
        Non-Platinum* 34 0.76 (0.18) 0.77 (0.14)
    Radiotherapy 34 0.80 (0.14) 0.83 (0.15)
    Chemoradiotherapy 308 0.78 (0.18) 0.82 (0.15)
        Platinum 175 0.77 (0.20) 0.82 (0.09)
        Non-Platinum 95 0.79 (0.16) 0.83 (0.08)
    No Treatment 26 0.81 (0.17) 0.82 (0.08)

Stage IV 628 0.76 (0.19) 0.82 (0.15)
    Surgery 17 0.69 (0.25) 0.71 (0.41)
    Chemotherapy 214 0.79 (0.19) 0.82 (0.09)
        Platinum 78 0.79 (0.17) 0.83 (0.08)
        Non-platinum 67 0.77 (0.21) 0.82 (0.10)
    Surgery w/Chemotherapy 33 0.80 (0.19) 0.83 (0.23)
        Platinum 19 0.84 (0.16) 0.83 (0.19)
    Surgery w/Chemoradiotherapy 29 0.74 (0.22) 0.82 (0.25)
        Non-Platinum 13 0.80 (0.13) 0.82 (0.08)
    Chest Radiation 29 0.72 (0.20) 0.80 (0.14)
    Chemoradiotherapy 270 0.75 (0.18) 0.79 (0.16)
        Platinum* 149 0.76 (0.17) 0.80 (0.15)
        Non-Platinum 82 0.75 (0.19) 0.78 (0.14)
        No Treatment 33 0.79 (0.17) 0.83 (0.10)
*

5-10% patients also received targeted therapy

10-15% patients also received targeted therapy

20-25% patients also received targeted therapy

§

35% patients also received targeted therapy